K

Keros Therapeutics
D

KROS

10.680
USD
-0.44
(-3.96%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
16,418
الربح لكل سهم
-5
العائد الربحي
-
P/E
-3
حجم السوق
211,754,368
نظرة عامة
أصول ذات صلة
BMRN
BMRN
D
BioMarin Pharmaceutical
54.687
-1.373(-2.45%)
BMY
BMY
D
Bristol-Myers Squibb Co
59.840
-0.740(-1.22%)
59.900+0.060(+0.10%)
EXEL
EXEL
D
Exelixis
62.250
-0.565(-0.90%)
IBB
IBB
D
iShares Biotechnology ETF
201.990
-5.420(-2.61%)
200.500-1.490(-0.74%)
INCY
INCY
D
Incyte Corp
113.140
-0.110(-0.10%)
TEVA
TEVA
D
Teva Pharmaceutical Industries Limited
41.490
0.365(0.89%)
T
TGTX
D
TG Therapeutics
53.990
-1.980(-3.54%)
XBI
XBI
D
SPDR S&P Biotech ETF
144.320
-5.460(-3.65%)
144.630+0.310(+0.21%)
المزيد

العنوان: Keros Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.